González Hernán F J, Yengo-Kahn Aaron, Englot Dario J
Department of Biomedical Engineering, Vanderbilt University Medical Center, 1500 21st Avenue South, 4340 Village at Vanderbilt, Nashville, TN 37232-8618, USA; Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, 1500 21st Avenue South, 4340 Village at Vanderbilt, Nashville, TN 37232-8618, USA.
Department of Neurological Surgery, Vanderbilt University Medical Center, 1121 21st Avenue South, Medical Center North, T4224, Nashville, TN 37232, USA.
Neurosurg Clin N Am. 2019 Apr;30(2):219-230. doi: 10.1016/j.nec.2018.12.005.
Vagus nerve stimulation (VNS) was the first neuromodulation device approved for treatment of epilepsy. In more than 20 years of study, VNS has consistently demonstrated efficacy in treating epilepsy. After 2 years, approximately 50% of patients experience at least 50% reduced seizure frequency. Adverse events with VNS treatment are rare and include surgical adverse events (including infection, vocal cord paresis, and so forth) and stimulation side effects (hoarseness, voice change, and cough). Future developments in VNS, including closed-loop and noninvasive stimulation, may reduce side effects or increase efficacy of VNS.
迷走神经刺激（VNS）是首个被批准用于治疗癫痫的神经调节装置。在20多年的研究中，VNS在治疗癫痫方面一直显示出疗效。两年后，约50%的患者癫痫发作频率至少降低50%。VNS治疗的不良事件很少见，包括手术相关不良事件（如感染、声带麻痹等）和刺激副作用（如声音嘶哑、嗓音改变和咳嗽）。VNS的未来发展，包括闭环和非侵入性刺激，可能会减少副作用或提高VNS的疗效。
